Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders].
Grupo de expertos del Grupo de Estudio de Sida (GeSIDA) y de la Secretaría del Plan Nacional sobre el Sida (SPNS); Podzamczer Palter D, Muñoz-Moreno JA, Alcolea Rodríguez D, Alonso Villaverde C, Antela López A, Blanch Andreu J, Casado Osorio JL, Galindo Puerto MJ, Garolera i Freixa M, Locutura Rupérez J, Lleó Bisa A, Prats París A, Pérez-Valero I, Portilla Sogorb J, Rovira Cañellas A, Téllez Molina MJ, Tiraboschi JM, Vergara Moragues E, Arribas López JR, Goenaga Sánchez MÁ, de León-Naranjo FL, Martínez Chamorro E, Polo Rodríguez R, Muñoz-Moreno JA, Podzamczer D. Grupo de expertos del Grupo de Estudio de Sida (GeSIDA) y de la Secretaría del Plan Nacional sobre el Sida (SPNS), et al. Among authors: tiraboschi jm. Enferm Infecc Microbiol Clin. 2014 Jan;32(1):37-47. doi: 10.1016/j.eimc.2013.03.005. Epub 2013 Apr 30. Enferm Infecc Microbiol Clin. 2014. PMID: 23642283 Spanish.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti AJ, Dalmau D, Casabona J, Miró JM, Falcó V; PISCIS study group. Burgos J, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):108-116. doi: 10.1093/jac/dkac361. J Antimicrob Chemother. 2022. PMID: 36308326
85 results